1. Home
  2. IMMP vs DENN Comparison

IMMP vs DENN Comparison

Compare IMMP & DENN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$3.15

Market Cap

264.9M

Sector

Health Care

ML Signal

HOLD

Logo Denny's Corporation

DENN

Denny's Corporation

HOLD

Current Price

$6.22

Market Cap

319.8M

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMMP
DENN
Founded
1987
1953
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
264.9M
319.8M
IPO Year
N/A
1989

Fundamental Metrics

Financial Performance
Metric
IMMP
DENN
Price
$3.15
$6.22
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$5.45
AVG Volume (30 Days)
1.9M
1.8M
Earning Date
02-22-2026
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.20
Revenue
$3,306,742.00
$457,212,000.00
Revenue This Year
$292.48
$6.56
Revenue Next Year
N/A
$1.56
P/E Ratio
N/A
$31.66
Revenue Growth
31.28
0.93
52 Week Low
$1.32
$2.85
52 Week High
$3.53
$7.66

Technical Indicators

Market Signals
Indicator
IMMP
DENN
Relative Strength Index (RSI) 78.17 66.18
Support Level $2.52 $6.13
Resistance Level $2.86 $6.24
Average True Range (ATR) 0.32 0.02
MACD 0.08 -0.03
Stochastic Oscillator 75.50 64.29

Price Performance

Historical Comparison
IMMP
DENN

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

About DENN Denny's Corporation

Denny's Corp is America's franchised full-service restaurant chains based on the number of restaurants. The company owns and operates the Denny's brand and the Keke's Breakfast Cafe brand. It provides Pancakes, Appetizers & Soups, Sandwiches & Salads, Breakfast Melts, Omelets, and others. The company generates its revenue from two sources: the sale of food and beverages and the collection of royalties, advertising revenue, initial and other fees, including occupancy revenue, from restaurants operated by their franchisees. Geographically operates in USA states as well as globally like Canada, Mexico, Guatemala, Indonesia, United Kingdom, New Zealand and others. Maximum revenue is from USA and Canada.

Share on Social Networks: